Variation in prostate specific antigen results from 2 different assay platforms: Clinical impact on 2,304 patients undergoing prostate cancer screening

Journal of Urology

Volumn 171, Issue 6 I, 2004, Pages 2234-2238

  Link, Richard E ^b   Shariat, Shahrokh F ^b   Nguyen, Cuong V ^b   Farr, Anita ^b   Weinberg, Armin D ^b   Morton, Ronald A ^b   Richardson, Barbara ^b   Bernard, David ^b   Slawin, Kevin M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Biopsy; Mass screening; Prostate; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; CALIBRATION; CANCER SCREENING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; METHODOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REFERENCE VALUE; WILCOXON SIGNED RANKS TEST;

EID: 2442526439     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000127736.86597.e7     Document Type: Article

References (20)

1. Mikolajczyk, S. D., Marker, K. M., Millar, L. S., Kumar, A., Saedi, M. S., Payne, J. K. et al: A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res, 61: 6958, 2001
2. Semjonow, A., Brandt, B., Oberpenning, F., Roth, S. and Hertle, L.: Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl, 7: 3, 1996
3. Graves, H. C. B., Wehner, N. and Stamey, T. A.: Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard. J Urol, 144: 1516, 1990
4. Roehrborn, C. G., Gregory, A., McConnell, J. D., Saglowsky, A. I. and Wians, F. H., Jr.: Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology, 48: 23, 1996
5. Dnistrian, A. M., Schwartz, M. K., Smith, C. A., Nisselbaum, J. S. and Fair, W. S.: Abbott IMx evaluated for assay of prostate-specific antigen in serum. Clin Chem, 38: 2140, 1992
6. Prostate-specific antigen (PSA) best practice policy. American Urological and Association. Oncology, 14: 267, 2000
7. Babaian, R. J., Johnston, D. A., Naccarato, W., Ayala, A., Bhadkamkar, V. A. and Fritsche, H. A., Jr.: The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng./ml.: relation to biopsy strategy. J Urol, 165: 757, 2001
8. Okihara, K., Fritsche, H. A., Ayala, A., Johnston, D. A., Allard, W. J. and Babaian, R. J.: Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol, 165: 1930, 2001
9. Gore, J. L., Shariat, S. F., Miles, B. J., Kadmon, D., Jiang, N., Wheeler, T. M. et al: Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol, 165: 1554, 2001
10. United States Census Bureau, 2000 Census of Population and Housing, Summary Population and Housing Characteristics, PHC-1-45, Texas. Washington, D. C.: United States Government Printing Office, 2002
11. Meigs, J. B., Mohr, B., Barry, M. J., Collins, M. M. and McKinlay, J. B.: Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol, 54: 935, 2001
12. Mikolajczyk, S. D., Millar, L. S., Marker, K. M., Wang, J. T., Rittenhouse, H. G., Marks, L. S. et al: Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate, 45: 271, 2000
13. Rafferty, B., Rigsby, P., Rose, M., Stanley, T. and Gaines Das, R.: Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90: 10). Clin Chem, 46: 1310, 2000
14. Kadmon, D., Weinberg, A. D., Williams, R. H., Pavlik, V. N., Cooper, P. and Migliore, P. J.: Pitfalls in interpreting prostate specific antigen velocity. J Urol, 155: 1655, 1996
15. Kalish, L. A. and McKinlay, J. B.: Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA. Urology, 54: 1022, 1999
16. Morgan, T. O., Jacobsen, S. J., McCarthy, W. F., Jacobson, D. J., McLeod, D. G. and Moul, J. W.: Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med, 335: 304, 1996
17. Catalona, W. J., Southwick, P. C., Slawin, K. M., Partin, A. W., Brawer, M. K., Flannigan, R. C. et al: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 56: 255, 2000
18. DeAntoni, E. P., Crawford, E. D., Oesterling, J. E., Ross, C. A., Berger, E. R., McLeod, D. G. et al: Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology, 48: 234, 1996
19. Oesterling, J. E., Jacobsen, S. J., Klee, G. G., Pettersson, K., Piironen, T., Abrahamsson, P.-A. et al: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol, 154: 1090, 1995
20. Kao, C. H.: Age-related free PSA, total PSA and free PSA/total PSA ratios: establishment of reference ranges in Chinese males. Anticancer Res, 17: 1361, 1997